The Biosimilars Market is being driven by Price advantage of biosimilars over biologics
The Biosimilars Market is expected to grow at a CAGR of 34.2% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 117678.1 million. In the global biosimilar market, patient acceptance of biosimilar switching and physician prescribing behavior significantly influence market growth. Many physicians, particularly rheumatologists, often prefer prescribing the bio-originator over biosimilars as the initial or secondary treatment option for rheumatology diseases. This resistance stems from concerns regarding the perceived reduced efficacy of biosimilars compared to the reference product. At the community pharmacy level, substitution of a biosimilar with a bio-originator is authorized in specific countries, primarily in Central and Eastern Europe. Despite an increasing trend in patient and physician adoption of biosimilars, the rate of substitution remains low due to regulatory restrictions in certain regions.
Get more information on Biosimilars Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
219 |
Base year |
2024 |
Historic period |
2019-2023 |
Forecast period |
2025-2029 |
Growth momentum & CAGR |
Accelerate at a CAGR of 34.2% |
Market growth 2025-2029 |
USD 117678.1 million |
Market structure |
market_structure.ucfirst |
YoY growth 2024-2025(%) |
25.6 |
Key countries |
Germany, US, UK, China, Canada, France, South Korea, Japan, Brazil, and UAE |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Biosimilars Market encompasses the regulatory landscape, intellectual property considerations, and patent litigation surrounding biosimilar products. Key elements include guidelines for regulatory approval, frameworks for manufacturing technology and analytical methods, clinical endpoint assessment, and data analysis. Market research, analysis, and intelligence provide insights into industry trends, dynamics, innovation, and access initiatives. Quality assurance, control, and risk assessment ensure safety and cost-effectiveness, while supply chain and distribution strategies optimize market penetration. Education programs and awareness campaigns enhance patient safety and understanding.
The biosimilars market represents a significant segment within the larger pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of these biologically similar alternatives to reference products. Monoclonal antibodies are a key therapeutic area for biosimilars, with increasing demand driven by their efficacy and cost savings compared to original biologics. The regulatory approval process for biosimilars is rigorous, requiring extensive clinical trials and comparisons to the reference product to ensure safety and efficacy. Technavio projects that the global pharmaceuticals market, which includes the revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, will experience growth due to demographic trends, such as an aging population. By 2050, approximately one-quarter of the US population and by 2030 in Europe, are projected to be over the age of 60 years, leading to a greater need for healthcare solutions, including biosimilars.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted